• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Turing's Martin Shkreli Arrested


December 17, 2015.

Reuters reports that Martin Shkreli, the controversial chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals, was arrested in New York today on securities fraud charges involving his former hedge fund, MSMB Capital Management, and a pharma company he previously headed, Retrophin Inc.   A Reuters reporter witnessed Shkreli's arrest at the Murray Hill Tower Apartments in Manhattan, NY. He FBI agents escorted Shkreli, who was wearing a hoodie, into a car. FBI spokeswoman Kelly Langmesser later confirmed the arrests of both Shkreli and Evan Greebel, a former partner at law firm Katten Muchin Rosenmann, which acted as Retrophin's outside counsel.   Turing and KaloBios have so far declined to comment on the news.    See the Reuters report here.

Related Videos